Funding Round attributes
Jinko, a health tech startup specializing in post-cancer care, has successfully raised €2 million in funding to advance its mission of improving the lives of cancer survivors. The funding round was led by 360 Capital, with participation from AFI Ventures and 10 business angels from the medical, entrepreneurial, insurance, and pharmaceutical sectors. The company's platform focuses on providing personalized post-treatment care plans, resources, and tools to help individuals in their recovery journey after cancer treatment. With this new capital, Jinko plans to expand its platform, enhance its service offerings, and increase its reach to support more users. This funding marks a significant step in the company’s growth and ability to serve a larger patient population.
The raised capital will be used to further develop the company's core technology and improve the overall user experience. Jinko’s platform addresses the challenges faced by cancer survivors, providing them with tailored resources to assist in their recovery. As cancer survivors often deal with long-term effects after treatment, Jinko’s focus is on creating a comprehensive solution that helps patients maintain a better quality of life.
The investment will enable Jinko to scale its platform by building new features, expanding into new markets, and enhancing its outreach to healthcare professionals. By doing so, Jinko aims to create an even more impactful and effective resource for post-cancer care, offering much-needed support for survivors as they transition into life after treatment.
The funding round highlights the importance of post-cancer care in the healthcare sector, as more attention is being given to the well-being of survivors beyond their initial treatment phase. Jinko’s innovative approach, backed by this latest investment, is set to make a significant contribution to the health tech industry, focusing on long-term wellness and recovery.
In conclusion, Jinko’s €2 million funding round will play a pivotal role in expanding the company’s post-cancer care platform. With plans to improve and scale its services, the company is well-positioned to make a meaningful impact on the lives of cancer survivors.
